Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib Combinations in Advanced Solid Tumors
NCT02077933Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of alpelisib in solid tumor (advanced stage), renal cell carcinoma (RCC), Pancreatic neuroendocrine tumor (PanNET) and 1 more (3 arms), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicity and Number of patients with adverse events. Started May 2014; status: completed.
02
Drugs
alpelisib
03
Conditions
solid tumor (advanced stage)renal cell carcinoma (RCC)Pancreatic neuroendocrine tumor (PanNET)breast cancer
Beyond the preview
Go deeper on NCT02077933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077933.